Cidara Therapeutics, Inc. (CDTX)
CDTX Stock Price Chart
Explore Cidara Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CDTX price movements and trends.
CDTX Company Profile
Discover essential business fundamentals and corporate details for Cidara Therapeutics, Inc. (CDTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Apr 2015
Employees
38.00
Website
https://www.cidara.comCEO
Jeffrey L. Stein
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
CDTX Financial Timeline
Browse a chronological timeline of Cidara Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.24.
Earnings released on 7 Aug 2025
EPS came in at -$1.65 surpassing the estimated -$1.87 by +11.76%.
Earnings released on 8 May 2025
EPS came in at -$1.66 surpassing the estimated -$5.45 by +69.54%.
Earnings released on 6 Mar 2025
EPS came in at -$5.38 falling short of the estimated -$5.28 by -1.89%.
Earnings released on 7 Nov 2024
EPS came in at -$2.38 surpassing the estimated -$5.22 by +54.41%.
Earnings released on 13 Aug 2024
EPS came in at -$2.05 surpassing the estimated -$3.94 by +47.97%, while revenue for the quarter reached $302.00K , missing expectations by -93.57%.
Stock split effective on 24 Apr 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 22 Apr 2024
EPS came in at -$0.80 falling short of the estimated -$0.20 by -300.00%, while revenue for the quarter reached $8.46M , beating expectations by +34.33%.
Earnings released on 28 Mar 2024
EPS came in at -$0.19 falling short of the estimated -$0.10 by -90.00%, while revenue for the quarter reached $17.58M , beating expectations by +52.37%.
Earnings released on 2 Nov 2023
EPS came in at -$1.80 surpassing the estimated -$2.80 by +35.71%, while revenue for the quarter reached $12.72M , beating expectations by +10.21%.
Earnings released on 3 Aug 2023
EPS came in at -$2.80 falling short of the estimated -$1.60 by -75.00%, while revenue for the quarter reached $7.61M , missing expectations by -34.08%.
Earnings released on 11 May 2023
EPS came in at $0.60 falling short of the estimated $1.20 by -50.00%, while revenue for the quarter reached $26.11M , beating expectations by +39.76%.
Earnings released on 23 Mar 2023
EPS came in at -$3.80 falling short of the estimated -$0.20 by -1.80K%, while revenue for the quarter reached $10.22M , missing expectations by -3.32%.
Earnings released on 3 Nov 2022
EPS came in at $3.40 falling short of the estimated $6.00 by -43.33%, while revenue for the quarter reached $40.74M , beating expectations by +43.73%.
Earnings released on 9 Aug 2022
EPS came in at -$3.80 surpassing the estimated -$5.60 by +32.14%, while revenue for the quarter reached $6.22M , beating expectations by +0.16%.
Earnings released on 11 May 2022
EPS came in at -$5.40 falling short of the estimated -$5.20 by -3.85%, while revenue for the quarter reached $7.11M , beating expectations by +20.69%.
Earnings released on 7 Mar 2022
EPS came in at -$5.20 surpassing the estimated -$6.60 by +21.21%, while revenue for the quarter reached $7.23M , beating expectations by +67.62%.
Earnings released on 10 Nov 2021
EPS came in at -$7.40 matching the estimated -$7.40, while revenue for the quarter reached $7.08M , meeting expectations.
Earnings released on 12 Aug 2021
EPS came in at $3.60 surpassing the estimated -$5.40 by +166.67%, while revenue for the quarter reached $32.86M , beating expectations by +80.57%.
Earnings released on 13 May 2021
EPS came in at -$7.80 falling short of the estimated -$3.40 by -129.41%, while revenue for the quarter reached $2.41M , beating expectations by +21.21%.
Earnings released on 25 Feb 2021
EPS came in at -$9.80 falling short of the estimated -$2.80 by -250.00%, while revenue for the quarter reached $3.73M , beating expectations by +27.70%.
Earnings released on 5 Nov 2020
EPS came in at -$8.20 surpassing the estimated -$9.60 by +14.58%, while revenue for the quarter reached $2.42M , beating expectations by +7.89%.
CDTX Stock Performance
Access detailed CDTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.